Minho Park

Ms. Minho Park


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2018 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Ji-Hun AnJi-Hun An
Ji-Hun An
CLChangjin Lim
Changjin Lim
AKAlice Nguvoko Kiyonga
Alice Nguvoko Kiyonga
ICIn Hwa Chung
In Hwa Chung
ILIn Kyu Lee
In Kyu Lee
KJKiwon Jung
Kiwon Jung
In the present study, the screening of Mirabegron (MBR) co-amorphous was performed to produce water-soluble and thermodynamically stable MBR co-amorphous with the purpose of overcoming the water solubility problem of MBR. MBR is Biopharmaceutics Classification System (BCS) class II drug used for the treatment of an overreactive bladder. The co-amorphous screening was carried out by means of the vacuum evaporation crystallization technique in methanol solvent using three water-soluble carboxylic acids, characterized by a pKa difference greater than 3 with MBR such as fumaric acid (FA), l-pyroglutamic acid (PG), and citric acid (CA). Powder X-ray diffraction (PXRD) results suggested that all solid materials produced at MBR-FA (1 equivalent (eq.)/1 equivalent (eq.)), MBR-PG (1 eq./1 eq.), and MBR-CA (1 eq./1 eq.) conditions were amorphous state solid materials. Furthermore, by means of solution-state nuclear magnetic resonance (NMR) (1H, 13C, and 2D) and attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy, we could assess that MBR and carboxylic acid molecules were linked via ionic interactions to produce MBR co-amorphous. Besides, solid-state cross polarization (CP)/magic angle spinning (MAS) 13C-NMR analysis was conducted for additional assessment of MBR co-amorphous. Afterwards, dissolution tests of MBR co-amorphouses, MBR crystalline solid, and MBR amorphous were carried out for 12 h to evaluate and to compare their solubilities, dissolution rates, and phase transformation phenomenon. Here, the results suggested that MBR co-amorphouses displayed more than 57-fold higher aqueous solubility compared to MBR crystalline solid, and PXRD monitoring result suggested that MBR co-amorphouses were able to maintain their amorphous state for more than 12 h. The same results revealed that MBR amorphous exhibited increased solubility of approximatively 6.7-fold higher compared to MBR crystalline solid. However, the PXRD monitoring result suggested that MBR amorphous undergo rapid phase transformation to crystalline form in just 35 min and that within an hour all MBR amorphous are completely converted to crystalline solid. Accordingly, the increase in MBR co-amorphous’ solubility was attributed to the presence of ionic interactions in MBR co-amorphous molecules. Moreover, from the differential scanning calorimetry (DSC) monitoring results, we predicted that the high glass transition temperature (Tg) of MBR co-amorphous compared to MBR amorphous was the main factor influencing the phase stability of MBR co-amorphous.

8 December 2017 in Crystals
Verified
Journal Article
Open access
PDF file
Ji-Hun AnJi-Hun An
Ji-Hun An
CLChangjin Lim
Changjin Lim
HRHyung Chul Ryu
Hyung Chul Ryu
JKJae Sun Kim
Jae Sun Kim
HKHyuk Min Kim
Hyuk Min Kim
KJKiwon Jung
Kiwon Jung
Febuxostat (FB) is a poorly water-soluble drug that belongs to BCS class II. The drug is employed for the treatment of inflammatory disease arthritis urica (gout), and the free base, FB form-A, is most preferred for drug formulation. In order to achieve a goal of improving the water solubility of FB form-A, this study was carried out using the cocrystallization technique called the liquid-assisted grinding method to produce FB cocrystals. Here, five amino acids containing amine (NH), oxygen (O), and hydroxyl (OH) functional groups, and possessing difference of pKa less than 3 with FB, were selected as coformers. Then, solvents including methanol, ethanol, isopropyl alcohol, n-hexane, dichloromethane, and acetone were used for the cocrystal screening. As a result, a cocrystal was obtained when acetone and l-pyroglutamic acid (PG) of 0.5 eq. were employed as solvent and coformer, respectively. The ratio of 2:1, which is the ratio of FB to PG within FB-PG cocrystal, was predicted by means of solid-state CP/MAS 13C-NMR, solution-state NMR (1H, 13C, and 2D) and FT-IR. Moreover, Powder X-ray Diffraction (PXRD), Differential Scanning Calorimetry (DSC), and Thermogravimetric Analysis (TGA) were used to investigate the characteristics of FB-PG cocrystal. In addition, comparative solubility tests between FB-PG cocrystal and FB form-A were conducted in deionized water and under simulated gastrointestinal pH (1.2, 4, and 6.8) conditions. The result revealed that FB-PG cocrystal has a solubility of four-fold higher than FB form-A in deionized water and two-fold and five-fold greater than FB form-A at simulated gastrointestinal pH 1.2 and pH 4, respectively. Besides, solubilities of FB-PG cocrystal and FB form-A at pH 6.8 were similar to the results measured in deionized water. Therefore, it is postulated that FB-PG cocrystal has a potential overcoming the limitations related to the low aqueous solubility of FB form-A. Accordingly, FB-PG cocrystal is suggested as an alternative active pharmaceutical ingredient of the currently used FB form-A.

14 July 2017 in Molecules
Verified
Journal Article
Open access
PDF file
Ji-Hun AnJi-Hun An
Ji-Hun An
AKAlice Nguvoko Kiyonga
Alice Nguvoko Kiyonga
WYWoojin Yoon
Woojin Yoon
HRHyung Chul Ryu
Hyung Chul Ryu
JKJae-Sun Kim
Jae-Sun Kim
KJKiwon Jung
Kiwon Jung
Tenofovir disoproxil (TD), an anti-virus drug, is currently marketed under its most stable form, Form-I of Tenofovir disoproxil fumarate (TDF). However, studies regarding the properties of TD free base crystal as a promising drug as well as its crystal structure have not yet been reported. This assumption was made because TD free base is not directly produced in a solid form during the manufacturing process. TD free base is first obtained in an oil form, and is then synthesized into TDF crystal. In this regard, the present study was conducted to investigate both the potentiality of TD free base to be an active pharmaceutical ingredient (API) and its crystal structure. Here, TD free base solid was produced by means of drowning-out crystallization. Next, single crystal X-ray diffraction (SXD) was employed to determine the crystal structure. Powder X-ray diffraction (PXRD) and a differential scanning calorimetry (DSC) analysis were performed to evaluate the crystal’s properties. Furthermore, experiments were carried out at 15%, 35%, 55%, 75%, and 95% relative humidity (RH) for 12 h using a hygroscopic tester to determine and to compare the hygroscopicity and stability of TD free base with TDF crystal. Additionally, experiments were conducted under accelerated (40 °C, RH 75%) and stress storage (60 °C, RH 75%) conditions for 30 days to investigate the changes in purity and the formation of dimer. In this work, we report that TD free base possesses lower hygroscopicity, and thus does not generate dimer impurity from hydrolysis. Primarily, this is attributed to the fact that TD free base is not an easily ionized salt but comprises neutral hydrophobic molecules. According to the structural properties, the improved hygroscopic property of the TD free base crystal was due to the decrease of crystal polarity owing to the intermolecular H-bonds present in TD free base rings. In addition, the solubility investigation study carried out in aqueous solution and at gastrointestinal pH revealed a similarity in TDF and TD free base solubility under the mentioned conditions. Accordingly, we could confirm the potentiality of TD free base as an active pharmaceutical ingredient.

1 October 2018 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Ji-Hun AnJi-Hun An
Ji-Hun An
WYWonno Youn
Wonno Youn
AKAlice Nguvoko Kiyonga
Alice Nguvoko Kiyonga
CLChangjin Lim
Changjin Lim
MPMinho Park
Minho Park
KJKiwon Jung
Kiwon Jung
Research studies related to the polymorphs of l-Carnitine orotate (CO), a medication used for the treatment and prevention of liver diseases, are insignificant or almost nonexistent. Accordingly, in the present study, l-Carnitine orotate (CO) was prepared for investigating CO polymorphs. Here, a reactive crystallization was induced by reacting 1g of l-Carn (1 equivalent) and 0.97 g of OA (1 equivalent) in methanol (MeOH); as a result, CO form-I and CO form-II polymorphs were obtained after 1 h and 16 h of stirring, respectively. The characterization of CO polymorphs was carried out utilizing Powder X-ray diffraction (PXRD), Differential Scanning Calorimetry (DSC), Thermogravimetric Analysis (TGA) and solid-state Nuclear Magnetic Resonance Spectroscopy (solid-state CP/MAS 13C-NMR). The solution-mediated polymorphic transformation (SMPT) of CO polymorphs was investigated in MeOH at controlled temperature and fixed rotational speed. The results revealed that CO form-I is a metastable polymorph while CO form-II is a stable polymorph. From the same results, it was confirmed that CO form-I was converted to CO form-II during the polymorphic phase transformation process. Moreover, it was assessed that the increase in temperature and supersaturation level significantly promotes the rate of nucleation, as well as the rate of mass transfer of CO form-II. In addition, nucleation and mass transfer equations were employed for the quantitative determination of SMPT experimental results. Lastly, it was suggested that CO form-II was more thermodynamically stable than CO form-I and that both polymorphs belong to the monotropic system.

23 September 2017 in Crystals
Verified
Journal Article
Open access
PDF file
Ji-Hun AnJi-Hun An
Ji-Hun An
AKAlice Nguvoko Kiyonga
Alice Nguvoko Kiyonga
WYWoojin Yoon
Woojin Yoon
MPMinho Park
Minho Park
CLChangjin Lim
Changjin Lim
KJKiwon Jung
Kiwon Jung
The present work aims to investigate the applicability of ionic liquids (ILs) for natural ingredient crystallization. First, the medicinal plant, namely Angelica gigas Nakai, was extracted using methanol (MeOH) as a solvent. Afterwards, ILs 1-butyl-3-methylimidazolium tetrafluoroborate (BMImBF4), 1-butyl-3-methylimidazolium hexafluorophosphate (BMImPF6), 1-butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide (BMImTFSI), 1-allyl-3-ethylim idazolium tetrafluoroborate (AEImBF4), and 1,3-diallyl imidazolium tetrafluoroborate (AAImBF4), in three ratios of 1:1, 1:2, and 1:3 (extraction solution/ILs (v/v)) were used as an anti-solvent to induce crystallization. Crystals were obtained within 8 h and were then identified to be pure crystals of sucrose through nuclear magnetic resonance (1H-NMR) analysis. Moreover, the single-crystal X-ray diffraction (SXD) analysis revealed all recovered crystals have an identical crystal structure and the morphology was monitored using a video microscope. With the application of BMImBF4 and BMImPF6, transformation of sucrose crystal morphology from an elongated hexagon shape to an elongated rectangular shape was observed with respect to the respective concentration increase. Here, all crystals precipitated from BMImBF4 and BMImPF6 were found to possess identical PXRD patterns. However, when BMImTFSI was employed, small rectangular crystals attached to the larger rectangular-shaped crystals due to secondary nucleation and shapeless amorphous forms were observed according to the alteration in the solution to ILs ratio. Accordingly, the ability of ILs as a relevant anti-solvent for the selective crystallization of a single compound from a natural product was assessed through the study. Furthermore, the applicability of ILs as crystal engineering solvents are expected to modify both the solid state and the crystal morphology of natural compounds, which can influence drug manufacturability, dissolution rate, and bioavailability.